Omninet Capital

Pattern Bioscience is a privately held in vitro diagnostics company founded in 2016 to help combat the problem of antibiotic resistance. Pattern is developing a next-generation clinical microbiology platform based on its patented phenotypic single-cell technology that can rapidly identify pathogens and determine their antibiotic response without the need for traditional time-consuming culture steps. Pattern’s Digital CultureTM technology relies on functional endpoints that encompass all possible resistance mechanisms, resulting in a more comprehensive and reliable diagnosis compared to rapid genotypic tests. The platform will deliver more reliable diagnoses days faster than the current standard of care.

Beyond Verbal Communication, Ltd. specializes in cloud-based emotion analytics that interpret human emotions and character traits through vocal intonations. Founded in 2012 and based in Tel Aviv, Israel, the company offers a solution that quantifies emotional variables such as valence, arousal, temper, mood groups, and combined emotions. This technology enhances voice-powered devices, systems, and applications by enabling them to understand and analyze emotions, thereby integrating emotional intelligence into digital platforms. Beyond Verbal's applications extend to market research, providing insights into consumer emotions and attitudes, as well as emotional wellness tracking to monitor significant changes in individuals' wellbeing. Additionally, the company collaborates with medical institutions to conduct clinical trials and big data projects that identify vocal biomarkers related to health conditions, facilitating continuous patient monitoring and predictive analytics. Beyond Verbal serves a global clientele across various sectors.

RADLogics Inc. develops radiology image analytics software platform for healthcare providers and radiologists. The company develops AlphaPoint, which searches, measures, characterizes, and prepares a preliminary findings report for CT, MRI, ultrasound, and X-ray scans using machine learning image analysis. Its solution uses machine-learning algorithms and takes advantage of accessing, aggregating, and analyzing data from thousands of factual clinical cases to deliver analysis for the case in hand. The company was founded in 2010 and is based in Piedmont, California.

Edeniq Inc. is a biotechnology company specializing in the conversion of cellulosic biomass into industrial sugars and cellulosic ethanol. Founded in 2006 and headquartered in Visalia, California, the company has developed innovative technologies, including the Cellunator, a device that enhances starch extraction from corn, and the Intellulose platform, which allows for the production of cellulosic ethanol from corn kernel fiber. Edeniq's solutions are designed for easy integration into existing ethanol production facilities without requiring significant capital investment. The company licenses its technologies to bio-refineries in the United States and Brazil, helping them improve efficiency and increase the yield of valuable biofuels and biochemicals.

Sonics is a pioneer of network-on-chip (NoC) technology and today offers SoC designers the largest portfolio of intelligent, on-chip communications solutions for home entertainment, wireless, networking and mobile devices. With a broad array of silicon-proven IP, Sonics helps designers eliminate memory bottlenecks associated with complex, high-speed SoC design, streamline and unify data flows and solve persistent network challenges in embedded systems with multiple cores. As the leading supplier of on-chip communications networks for the embedded market, Sonics has enabled its customers to ship more than 750 million units worldwide. Founded in 1996, Sonics is headquartered in Milpitas, Calif. with offices worldwide.

The company develops code division multiple access chipsets for wireless voice and data products.